arrow
J

Jason B. Cross

university of texas m d anderson cancer center
H指数:24
被引数:3,431

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Structure-Guided Development of NRAS G12D Inhibitors Based on a 5-Azaindole Core
2026-01-220
PRE
Allosteric targeting of RIPK1: discovery of novel inhibitors via parallel virtual screening and structure-guided optimization

别构靶向RIPK1:通过平行虚拟筛选和结构导向优化发现新型抑制剂

2025-09-270
PRE
Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid Cancers
2024-12-040
PRE
Discovery of IACS-52825, a Potent and Selective DLK Inhibitor for Treatment of Chemotherapy-Induced Peripheral Neuropathy
2023-07-129
PRE
Discovery of 6-[(3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor
2021-10-1323
PREAI
Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme

发现IACS-9779和IACS-70465作为靶向吲哚胺2,3-双加氧酶1 (IDO1) 脱辅酶的有效抑制剂

2021-07-2217
PREAI
Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib

变构SHP2抑制剂,IACS-13909克服了对奥希替尼的EGFR依赖性和EGFR非依赖性耐药机制

2020-11-0362
OAAI
Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R
2020-07-2913
PREAI
Discovery of IACS-13909, an allosteric SHP2 inhibitor that overcomes multiple mechanisms underlying osimertinib resistance
2019-12-011
PRE
IACS-9779, a development candidate that inhibits 2,3-dioxygenase (IDO) activity by blocking heme incorporation into IDO apoenzyme
2019-07-011
PRE
Discovery of an imidazopyridine series of potent human IDO1 inhibitors with robust target engagement in a preclinical tumor model
2018-07-010
PRE
An inhibitor of oxidative phosphorylation exploits cancer vulnerability
2018-06-11649
PREAI
IACS-010759, a novel inhibitor of complex I in Phase I clinical development to target OXPHOS dependent tumors
2017-07-010
PRE